Leukemia

Disease State Hub

Clinical Insights

Conference Coverage

Conference Coverage

Impact of Chemotherapy, Radiation in Patients Who Develop Acute Myeloid Leukemia, Myelodysplastic Syndrome

12/29/2023

Pinkal Desai, MD

In this podcast, Pinkal Desai, MD, discusses the impact of previous chemotherapy and/or radiation exposure in patients who go on to develop acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS),...

12/29/2023

Research Summaries

FDA Alert

FDA Grants Accelerated Approval for First CAR-T Cell Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/22/2024

Anthony Calabro, MA

The FDA previously approved lisocabtagene maraleucel as a second-line treatment option for adult patients with large B-cell lymphoma in June 2022.

04/22/2024

Conference Coverage

Study Finds Slightly Lower Risk of Richter Transformation for Patients With Chronic Lymphocytic Leukemia in the “Novel Agent Era”

03/13/2024

Anthony Calabro, MA

The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...

03/13/2024

Conference Coverage

Venetoclax-Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Improves PFS Compared With Venetoclax Alone

02/23/2024

Anthony Calabro, MA

Researchers assessed the efficacy of venetoclax-based treatments for patients with relapsed/refractory chronic lymphocytic leukemia. This study was presented at the 65th ASH Annual Meeting & Exposition...

02/23/2024

Conference Coverage

Ibrutinib Dose Adjustments Do Not Impact Time to Next Treatment For Patients With Chronic Lymphocytic Leukemia

01/31/2024

Anthony Calabro, MA

Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...

01/31/2024

Research Summary

MRD-Directed Therapy Improves Progression-Free Survival For Patients With Chronic Lymphocytic Leukemia vs Standard Treatment

01/29/2024

Anthony Calabro, MA

A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...

01/29/2024

April 2024

Current Issue

April 2024

Volume 64

Issue 4